GE HealthCare has launched CleaRecon DL, its AI-based 3D reconstruction technology to enhance the cone-beam computed tomography (CBCT) images in interventional suites.
The advanced solution, powered by deep-learning algorithms, has received the US Food and Drug Administration (FDA) 510(k) approval and a CE mark.
CleaRecon DL is designed to address the limitations of CBCT, which is essential in interventional procedures for its ability to provide detailed anatomical visualisation.
It aims to improve clinical outcomes by reducing streak artifacts caused by blood flow and contrast distribution during CBCT procedures.
However, image quality can be compromised by artifacts from vessel pulsatility, affecting clarity and accuracy.
The AI-driven solution seeks to overcome these challenges, enhancing confidence in CBCT image interpretation and its routine clinical adoption.
GE HealthCare interventional solutions general manager Arnaud Marie said: “The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT.
“By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence.
“This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes.”
CleaRecon DL features deep learning, an advanced AI technology The machine learning technique processes images using population-representative data and clinical testing.
The technology aims to deliver clearer and more precise imaging, supporting healthcare professionals in making informed decisions and improving patient care.
Clinical validation testing has showed the effectiveness of CleaRecon DL, with 98% of cases showing clearer images compared to conventional CBCT.
In addition, 94% of cases reported improved confidence in CBCT image interpretation.
GE HealthCare is currently offering CleaRecon DL in the European Union (EU) and US.
Denver, Colorado-based image guided therapy interventional radiologist Charles Nutting said: “CleaRecon DL takes CBCT to the next level, enabling clinicians to confidently use CBCT on patients with tools that help us provide the highest quality imaging and treatment across a wide range of clinical scenarios.
“This advancement improves our ability to perform precise interventions, with less manipulation of the image and eliminates artifacts that have historically hindered image clarity, ultimately helping improve the care clinicians can provide to patients.”
